Cindy Ung, MD
Ophthalmology · Boston, MANPI 1710305172
Payments from drug & device makers
Across 86 payments — averaging $71.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Alcon$897
- Regeneron Healthcare Solutions, Inc.$824
- Regeneron$806
- Genentech USA, Inc.$565
- Apellis Pharmaceuticals, Inc.$353
- plus $964 from 13 others
What the payments were for
- Consulting fees$1,47024%
- Travel & lodging$97416%
- Food & beverage$3,69460%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $1,750 |
| Alcon | 10 | $897 |
| Regeneron Healthcare Solutions, Inc. | 23 | $824 |
| Regeneron | 2 | $806 |
| Genentech USA, Inc. | 17 | $565 |
| Apellis Pharmaceuticals, Inc. | 3 | $353 |
| Astellas Pharma US Inc | 4 | $162 |
| Aerie Pharmaceuticals, Inc. | 3 | $152 |
| AbbVie | 6 | $139 |
| Genentech, Inc. | 1 | $131 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $90 |
| Alimera Sciences, Inc. | 3 | $90 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Coherus Oncology, Inc. | 1 | $28 |
| Amgen | 1 | $26 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Vyera Pharmaceuticals, LLC | 1 | $18 |
| Eyepoint US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,159 in reported general payments places this provider in the 80th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 25 | $1,246 |
| Brimonidine Tartrate | 27 | $1,090 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 48 | $771 |
| Latanoprost | 69 | $709 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 77 | $648 |
| Ketorolac Tromethamine | 36 | $629 |
| Dorzolamide Hcl | 18 | $268 |
| ErythromycinErythromycin Base | 16 | $157 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boston
- Jennifer SunBoston$4.2M
- Lloyd AielloBoston$3.1M
- Rishi SinghBoston$2.5M
- Jack GreinerBoston$523K
- Reza DanaBoston$510K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- David FriedmanBoston$259K
- Dean EliottBoston$250K
- Michael RaizmanBoston$237K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.